Abstract
To the Editor: Dupilumab facial redness (DFR) is an adverse event characterized by new-onset or paradoxical flaring of facial dermatitis reported in approximately 10% of patients receiving dupilumab. 1 Waldman R.A. DeWane M.E. Sloan B. Grant-Kels J.M. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020; 82: 230-232 Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar Unlike dupilumab ocular surface disease (DOSD), DFR was not reported in dupilumab clinical trials. 1 Waldman R.A. DeWane M.E. Sloan B. Grant-Kels J.M. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020; 82: 230-232 Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar Although dupilumab has been approved for the treatment of atopic dermatitis in children as young as 6 years, no dedicated studies have been performed to determine whether DFR occurs at similar rates in children and adults. A total of 225 patients were included in the 2 published retrospective chart reviews describing DFR, only 9 of whom are children. 1 Waldman R.A. DeWane M.E. Sloan B. Grant-Kels J.M. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020; 82: 230-232 Abstract Full Text Full Text PDF PubMed Scopus (42) Google Scholar ,2 Zhu G.A. Chen J.K. Chiou A. Ko J. Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019; 155: 850-852 Crossref PubMed Scopus (28) Google Scholar Here, this study aims to characterize DFR in the pediatric population.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
